ZOLMITRIPTAN TABLET

Country: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

ZOLMITRIPTAN

থেকে পাওয়া:

JUBILANT GENERICS LIMITED

এটিসি কোড:

N02CC03

INN (International Name):

ZOLMITRIPTAN

ডোজ:

2.5MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

ZOLMITRIPTAN 2.5MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

6

প্রেসক্রিপশন টাইপ:

Prescription

Therapeutic area:

SELECTIVE SEROTONIN AGONISTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0134381001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2014-01-21

পণ্য বৈশিষ্ট্য

_Zolmitriptan _
_Page 1 of 31 _
PRODUCT MONOGRAPH
PR
ZOLMITRIPTAN
Zolmitriptan
Tablets, 2.5 mg
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
SPONSOR: DATE OF REVISION:
Jubilant Generics Limited
March 27, 2020
1A- Sector 16A, Institutional Area,
Noida, Uttar Pradesh, India, 201301
DISTRIBUTOR:
Pharmapar Inc.,
1565 Boul. Lionel- Boulet, Varennes
QC J3X 1P7
SUBMISSION CONTROL NO.: 237077
_Zolmitriptan _
_Page 2 of 31 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...................................................
3
SUMMARY PRODUCT
INFORMATION.....................................................................
3
INDICATIONS AND CLINICAL
USE............................................................................
3
CONTRAINDICATIONS..................................................................................................
3
WARNINGS AND
PRECAUTIONS................................................................................
4
ADVERSE
REACTIONS..................................................................................................
10
DRUG
INTERACTIONS..................................................................................................
15
DOSAGE AND
ADMINISTRATION..............................................................................
17
OVERDOSAGE.................................................................................................................
18
ACTION AND CLINICAL
PHARMACOLOGY.............................................................
18
STORAGE AND
STABILITY..........................................................................................
20
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 20
PART II: SCIENTIFIC
INFORMATION..............................................................................
21
PHARMACEUTICAL
INFORMATION..........................................................................
21
CLINICAL
TRIALS.......................................................................................